Clinical Report: Evaluation of mortality risk in women with early-onset T2DM
Overview
This study investigates all-cause mortality risk among women with young-onset type 2 diabetes mellitus (YOD) and identifies key factors influencing mortality. Findings indicate that postmenopausal women with YOD have a higher mortality risk compared to their premenopausal counterparts, with triglyceride–glucose–body mass index (TyG-BMI) serving as a protective factor.
Background
The rising prevalence of young-onset type 2 diabetes mellitus (YOD) among women poses significant health challenges, including increased mortality risk. Understanding the factors contributing to mortality in this population is crucial for developing targeted interventions. This study addresses the gap in research regarding the epidemiology and mortality risk of YOD in women, particularly in the Chinese context.
Data Highlights
Group
All-Cause Mortality Rate
Young Menopausal (YM)
15%
Young Premenopausal (YP)
3.7%
Nonyoung Menopausal (NYM)
24%
Nonyoung Premenopausal (NYP)
Data not specified
Key Findings
The overall all-cause mortality rate for YOD patients was 21.6% over ten years.
Postmenopausal women (NYM) exhibited the highest mortality rate at 24%.
YP had the lowest mortality rate at 3.7%.
TyG-BMI was identified as an independent protective factor for the YM group (HR = 0.980).
Uric acid (UA) was a common risk factor for all age groups studied.
Clinical Implications
Healthcare providers should prioritize early identification and management of TyG-BMI levels in postmenopausal women with YOD to mitigate mortality risk. Understanding the differential mortality rates among various age and menopausal status groups can guide tailored interventions and monitoring strategies.
Conclusion
The study highlights the need for targeted interventions in postmenopausal women with YOD, emphasizing the protective role of TyG-BMI in reducing mortality risk. Continued research is essential to further elucidate the factors influencing mortality in this vulnerable population.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
